Agent‐Based Modeling in Systems Pharmacology

Modeling and simulation (M&S) techniques provide a platform for knowledge integration and hypothesis testing to gain insights into biological systems that would not be possible a priori. Agent‐based modeling (ABM) is an M&S technique that focuses on describing individual components rather than homogenous populations. This tutorial introduces ABM to systems pharmacologists, using relevant case studies to highlight how ABM‐specific strengths have yielded success in the area of preclinical mechanistic modeling.

[1]  Peter L. Bonate,et al.  Clinical Trial Simulation in Drug Development , 2000, Pharmaceutical Research.

[2]  M. Alamgir Hossain,et al.  A Hybrid Cellular Automaton Model of Solid Tumor Growth and Bioreductive Drug Transport , 2012, IEEE/ACM Transactions on Computational Biology and Bioinformatics.

[3]  C. Begley,et al.  Drug development: Raise standards for preclinical cancer research , 2012, Nature.

[4]  G. Victora,et al.  Clonal and cellular dynamics in germinal centers. , 2014, Current opinion in immunology.

[5]  Erwin P. Gianchandani,et al.  Characterizing emergent properties of immunological systems with multi-cellular rule-based computational modeling. , 2008, Trends in immunology.

[6]  J. Christian J. Ray,et al.  Synergy between Individual TNF-Dependent Functions Determines Granuloma Performance for Controlling Mycobacterium tuberculosis Infection1 , 2009, The Journal of Immunology.

[7]  Colin G. Johnson,et al.  Simulating complex intracellular processes using object-oriented computational modelling. , 2004, Progress in biophysics and molecular biology.

[8]  Vipin Kumar,et al.  Homeostatic control of immunity by TCR peptide-specific Tregs. , 2004, The Journal of clinical investigation.

[9]  Michel Goldman,et al.  Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. , 2005, The New England journal of medicine.

[10]  N Benson,et al.  Model‐Based Drug Development: A Rational Approach to Efficiently Accelerate Drug Development , 2013, Clinical pharmacology and therapeutics.

[11]  Susan Stepney,et al.  The CoSMoS Process, Version 0.1: A Process for the Modelling and Simulation of Complex Systems , 2010 .

[12]  Gilles Clermont,et al.  A Patient-Specific in silico Model of Inflammation and Healing Tested in Acute Vocal Fold Injury , 2008, PloS one.

[13]  Vipin Kumar,et al.  Techniques for grounding agent-based simulations in the real domain: a case study in experimental autoimmune encephalomyelitis , 2012 .

[14]  D. Kirschner,et al.  A methodology for performing global uncertainty and sensitivity analysis in systems biology. , 2008, Journal of theoretical biology.

[15]  Michael Meyer-Hermann,et al.  Germinal centres seen through the mathematical eye: B-cell models on the catwalk. , 2009, Trends in immunology.

[16]  Bruce Eckel.  Thinking in Java (2nd ed.): the definitive introduction to object-oriented programming in the language of the World-Wide Web , 1998 .

[17]  Darrel C. Ince,et al.  The case for open computer programs , 2012, Nature.

[18]  Birgit Müller,et al.  A standard protocol for describing individual-based and agent-based models , 2006 .

[19]  Mark J. Miller,et al.  Systems biology approaches for understanding cellular mechanisms of immunity in lymph nodes during infection. , 2011, Journal of theoretical biology.

[20]  Abdul Salam Jarrah,et al.  A Mathematical Framework for Agent Based Models of Complex Biological Networks , 2010, Bulletin of mathematical biology.

[21]  Olaf Wolkenhauer,et al.  Enabling multiscale modeling in systems medicine , 2014, Genome Medicine.

[22]  Jonathan Timmis,et al.  Spartan: A Comprehensive Tool for Understanding Uncertainty in Simulations of Biological Systems , 2013, PLoS Comput. Biol..

[23]  SRB Allerheiligen,et al.  Impact of Modeling and Simulation: Myth or Fact? , 2014, Clinical pharmacology and therapeutics.

[24]  A. Vargha,et al.  A Critique and Improvement of the CL Common Language Effect Size Statistics of McGraw and Wong , 2000 .

[25]  Hugues Bersini,et al.  State-Transition Diagrams for Biologists , 2012, PloS one.

[26]  A. Baxter,et al.  The origin and application of experimental autoimmune encephalomyelitis , 2007, Nature Reviews Immunology.

[27]  W. Hagopian,et al.  Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial , 2011, The Lancet.

[28]  Paul S. Andrews,et al.  Pairing experimentation and computational modeling to understand the role of tissue inducer cells in the development of lymphoid organs , 2012, Front. Immun..

[29]  Thomas S Deisboeck,et al.  The effects of EGF-receptor density on multiscale tumor growth patterns. , 2005, Journal of theoretical biology.

[30]  Barbara Marte,et al.  Tumour heterogeneity , 2013, Nature.

[31]  W Ewy,et al.  Model‐based Drug Development , 2007, Clinical pharmacology and therapeutics.

[32]  Le Zhang,et al.  Simulating brain tumor heterogeneity with a multiscale agent-based model: Linking molecular signatures, phenotypes and expansion rate , 2006, Math. Comput. Model..

[33]  Paul S. Andrews,et al.  Determining Disease Intervention Strategies Using Spatially Resolved Simulations , 2013, PloS one.

[34]  Jonathan R. Karr,et al.  A Whole-Cell Computational Model Predicts Phenotype from Genotype , 2012, Cell.

[35]  Paul S. Andrews,et al.  Using argument notation to engineer biological simulations with increased confidence , 2015, Journal of The Royal Society Interface.

[36]  L B Sheiner,et al.  Learning versus confirming in clinical drug development , 1997, Clinical pharmacology and therapeutics.

[37]  Alexey Solovyev,et al.  Hybrid Equation/Agent-Based Model of Ischemia-Induced Hyperemia and Pressure Ulcer Formation Predicts Greater Propensity to Ulcerate in Subjects with Spinal Cord Injury , 2013, PLoS Comput. Biol..

[38]  Gary C An,et al.  Translational systems biology using an agent‐based approach for dynamic knowledge representation: An evolutionary paradigm for biomedical research , 2010, Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society.

[39]  I. Cohen,et al.  Spontaneous remission of autoimmune encephalomyelitis is inhibited by splenectomy, thymectomy or ageing , 1980, Nature.

[40]  MC Peterson,et al.  FDA Advisory Meeting Clinical Pharmacology Review Utilizes a Quantitative Systems Pharmacology (QSP) Model: A Watershed Moment? , 2015, CPT: pharmacometrics & systems pharmacology.

[41]  Matthias von Herrath,et al.  Virtual Optimization of Nasal Insulin Therapy Predicts Immunization Frequency to Be Crucial for Diabetes Protection , 2010, Diabetes.

[42]  C. Glenn Begley,et al.  Raise standards for preclinical cancer research , 2012 .

[43]  Dirk Helbing,et al.  Social Self-Organization , 2012 .

[44]  SRB Allerheiligen,et al.  Next‐Generation Model‐Based Drug Discovery and Development: Quantitative and Systems Pharmacology , 2010, Clinical pharmacology and therapeutics.

[45]  Shayn M. Peirce,et al.  Agent-Based Model of Therapeutic Adipose-Derived Stromal Cell Trafficking during Ischemia Predicts Ability To Roll on P-Selectin , 2009, PLoS Comput. Biol..

[46]  Mark Read,et al.  Statistical and Modelling Techniques to Build Confidence in the Investigation of Immunology through Agent-Based Simulation , 2011 .

[47]  G. An.  In silico experiments of existing and hypothetical cytokine-directed clinical trials using agent-based modeling* , 2004, Critical care medicine.

[48]  Fiona A. C. Polack.  Choosing and adapting design notations in the principled development of complex systems simulations for research , 2012, MOTPW '12.

[49]  J. Southgate,et al.  Agent-based computational modeling of wounded epithelial cell monolayers , 2004, IEEE Transactions on NanoBioscience.

[50]  Glen E. P. Ropella,et al.  Moving beyond in silico tools to in silico science in support of drug development research , 2011 .

[51]  N. Sjögren,et al.  Effective visualization of integrated knowledge and data to enable informed decisions in drug development and translational medicine , 2013, Journal of Translational Medicine.

[52]  S. Visser,et al.  Implementation of Quantitative and Systems Pharmacology in Large Pharma , 2014, CPT: pharmacometrics & systems pharmacology.

[53]  Dagmar Iber,et al.  An analysis of B cell selection mechanisms in germinal centers. , 2006, Mathematical medicine and biology : a journal of the IMA.

[54]  J. C. Helton,et al.  Uncertainty and Sensitivity Analysis for Models of Complex Systems , 2008 .

[55]  J. Goverman.  Autoimmune T cell responses in the central nervous system , 2009, Nature Reviews Immunology.

[56]  Jason A. Papin,et al.  Mechanistic systems modeling to guide drug discovery and development. , 2013, Drug discovery today.

[57]  E. Sercarz,et al.  An integrative model of regulation centered on recognition of TCR peptide/MHC complexes , 2001, Immunological reviews.

[58]  M. Danhof,et al.  Modeling and Simulation at the Interface of Nonclinical and Early Clinical Drug Development , 2013, CPT: pharmacometrics & systems pharmacology.

[59]  Glen E. P. Ropella,et al.  Agent-based modeling: a systematic assessment of use cases and requirements for enhancing pharmaceutical research and development productivity , 2013, Wiley interdisciplinary reviews. Systems biology and medicine.

[60]  M. Mimeault,et al.  Hypoxia-inducing factors as master regulators of stemness properties and altered metabolism of cancer- and metastasis-initiating cells , 2013, Journal of cellular and molecular medicine.

[61]  Radojka M. Savic,et al.  Facilitating Drug Discovery and Development with Mechanistic Physiological Models that are "Fit for Purpose": Introducing a Model Qualification Method. , 2012 .

[62]  P. Mendes,et al.  Multi-scale modelling and simulation in systems biology. , 2011, Integrative biology : quantitative biosciences from nano to macro.

[63]  Zongguang Zhou,et al.  A tumor hypoxic niche protects human colon cancer stem cells from chemotherapy , 2013, Journal of Cancer Research and Clinical Oncology.

[64]  K. Toellner,et al.  Toll-like receptor 4 signaling by follicular dendritic cells is pivotal for germinal center onset and affinity maturation. , 2010, Immunity.

[65]  Jonathan Timmis,et al.  Automated calibration of agent-based immunological simulations , 2013, ECAL.

[66]  Forest M White,et al.  Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML. , 2012, Nature chemical biology.

[67]  Alan S. Perelson,et al.  Agent-based modeling of host–pathogen systems: The successes and challenges , 2008, Information Sciences.

[68]  Shayn M. Peirce,et al.  Combining experiments with multi-cell agent-based modeling to study biological tissue patterning , 2007, Briefings Bioinform..

[69]  John H. Reif,et al.  Successes and challenges , 2021, Strategic Community Partnerships, Philanthropy, and Nongovernmental Organization.

[70]  James Butler,et al.  Novel Approaches to the Visualization and Quantification of Biological Simulations by Emulating Experimental Techniques , 2014 .

[71]  G. An,et al.  Agent‐based models in translational systems biology , 2009, Wiley interdisciplinary reviews. Systems biology and medicine.